Post-Interleukin 6

Aktuelle Version vom 11. April 2021, 19:09 Uhr

siltuximab, tocilizumab, SGP130Fc, sarilumab, clazakizumab

a personal note: in early 1989 i got the seminal yasuhiru horii paper on il6 in mpgn and i decided to get ppl involved in making il6 inhibitors. it was a pretty sad experience and TOshio hirano and tadamitsu CIshimoto made their mice make TOCI-lizumab. With a little conservative misnomer of one digit.

32472703 2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.
32353761 2020. Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review
32247642 ä. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report
32243501 2020. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
32343968 ä. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report
32337664 ä. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
32359035 2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19
32378647 2020. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
32234467 ä. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
32305588 ä. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
32291137 ä. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
32300051 2020. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
C7154570 2020. Anti-IL6R role in treatment of COVID-19-related ARDS
32290839 2020. Why tocilizumab could be an effective treatment for severe COVID-19?
32372149 ä. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?
32367812 2020. Fyrsta meethfereth meeth tocilizumab vieth COVID-19 herlendis - sjukratilfelli
32327746 ä. Translating IL-6 biology into effective treatments
32325121 ä. Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19
32380318 ä. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection
32359210 2020. Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report
32324331 2020. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine
32376396 ä. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
32376398 ä. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
32299796 2020. Antirheumatic agents in covid-19: is IL-6 the right target?
32369612 2020. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma
32278585 2020. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab
32352361 2020. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists
32253759 2020. Tocilizumab treatment in COVID-19: A single center experience
32171193 2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies
32209313 2020. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws
32369191 2020. Tocilizumab for the treatment of severe coronavirus disease 2019
32297987 2020. Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection
32358817 2020. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome
32282956 2020. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab
C7187784 ä. Case Study: A Patient with Asthma, Covid-19 Pneumonia and Cytokine Release Syndrome Treated with Corticosteroids and Tocilizumab
32350134 2020. Effective treatment of severe COVID-19 patients with tocilizumab
32365207 ä. Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report
32376396 2020. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
32380318 2020. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection
32402416 ä. Perforacion intestinal en paciente COVID-19 en tratamiento con tocilizumab y corticoides ...

32389721 ä. Tocilizumab in COVID-19: Beware the risk of intestinal perforation
C7154570 2020. Anti-IL6R role in treatment of COVID-19-related ARDS
32393681 2020. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.
32387320 ä. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
32397399 2020. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).
32500936 2020. Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.
32391669 2020. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].
32436994 2020. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
32505467 2020. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
32492210 2020. Tocilizumab Administration in Patients with SARS-CoV-2 Infection: Subcutaneous Injection versus Intravenous Infusion.
32499314 2020. Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.
32503815 2020. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
32485858 2020. Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells.
32500858 2020. Serum concentrations of interleukin-6 (IL-6) in the general adult population: possible implications for anti-IL-6 therapy in SARS-Cov-2 infection and IL-6-related diseases.
32488861 2020. Applied Clinical Pharmacology in a Crisis - Interleukin-6 Axis Blockade and COVID-19.
32480422 2020. Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.
32457999 2020. Tocilizumab not associated with increased infection risk after CAR T - Implications for COVID-19?
32406282 2020. Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.
32452345 2020. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart.
32495916 2020. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
32470146 2020. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis.
32462717 2020. COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
32456769 2020. Early tocilizumab treatment could improve survival among COVID-19 patients.

32484930 2020. Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients.
32484915 2020. Feasibility of Tocilizumab in ICU patients with COVID-19.
32502524 2020. Tocilizumab administration in a refractory case of COVID-19.
32425661 2020. Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.
32421092 2020. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.
32476261 2020. Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2.
32386438 2020. 'Toxic erythema' and eosinophilia associated with tocilizumab therapy in a COVID-19 patient.
32482373 2020. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
32432518 2020. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.
32535732 2020. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
32482597 2020. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
32448770 2020. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
32425364 2020. Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation.
32405160 2020. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
32361193 2020. Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection.
32425662 2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.
32523930 2020. Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome.
32399455 2020. Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome.

32523147 2020. A... interleucina-6 en SARS-CoV-2/COVID-19.
32410234 2020. Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.
32478465 2020. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.
32406985 2020. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
32557214 2020. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.

32557206 2020. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.
32557541 2020. A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
32574789 2020. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
32569363 2020. Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case- Controlled Study.
32556278 2020. Real-life experience of tocilizumab use in COVID-19 patients.
32573990 2020. Heart Transplant Recipient Patient with COVID-19 Treated with Tocilizumab.
32593520 2020. Tocilizumab en nino con leucemia linfoblastica aguda y sindrome de liberacion de citoquinas asociado a COVID-19.
32553536 2020. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes.
32573419 2020. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
32575124 2020. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia.
32570043 2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.
32447665 2020. Mit IL-6-Inhibitor gegen COVID-19 : Corona-Pandemie.
32568411 2020. Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm.
32541085 2020. Citokinellenes terapia az uj tipusu koronavirus okozta megbetegedes (COVID-19) kezeleseben - tocilizumab elsokent valo alkalmazasa egy hazai infektologiai osztalyon.
32515499 2020. Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: a possible indication for deeper targeting IL-6.
32563584 2020. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report.
C7726269 2020. Ceftriaxone/hydroxychloroquine/tocilizumab: QT prolongation torsade-de-pointes and off label use: case report.
32512231 2020. Tuberculosis sepsis after tocilizumab treatment.
32628003 2020. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.
32635353 2020. Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.
32636755 2020. Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19.
32638109 2020. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
32639062 2020. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19.
32644027 2020. Tocilizumab for COVID-19: a real 'miracle drug'?
32644254 2020. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.
32646770 2020. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
32647027 2020. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.
32650019 2020. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.
32651997 2020. Tocilizumab for treatment of mechanically ventilated patients with COVID-19.
32652164 2020. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
32656822 2020. Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.
32661912 2020. Tocilizumab, Adipokines and Severe Complications of COVID-19.
32664810 2020. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
32670785 2020. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis.
32672860 2020. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
32683974 2020. Gastrointestinal Perforation After Treatment With Tocilizumab : An Unexpected Consequence of COVID-19 Pandemic.
32685369 2020. Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation.
32685300 2020. The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.
32690352 2020. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
32691021 2020. Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia.
32693650 2020. Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study.
32694244 2020. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.
32696008 2020. The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Patients Requiring Mechanical Ventilation: A Series of 21 Consecutive Cases.
32696570 2020. Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state.

32713677 ?. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.

32718713 ?. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.
32719045 2020. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
32719218 2020. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.

32727107 2020. Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.
32737106 2020. Rational use of tocilizumab in COVID-19.
32737112 2020. Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.
32737105 2020. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli.
32744399 2020. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.
32745348 2020. Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients.
32768693 2020. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
32768701 2020. Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation.
32776624 2020. Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia.
32784192 2020. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
32784217 2020. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
32790075 2020. Late onset infectious complications and safety of tocilizumab in the management of COVID-19.
32790733 2020. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
32793725 2020. Tocilizumab exerts anti-inflammatory activity in six critically ill COVID-19 patients: a retrospective analysis.
32798660 2020. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.
32801727 2020. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date.
32816957 2020. Bowel ulceration following tocilizumab administration in a COVID-19 patient.
32817707 2020. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
32818119 2020. Early Use of Tocilizumab May Prevent Clinical Deterioration in Select COVID-19 Patients: A Case Series.

32838235 2020. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up.
32838322 2020. The conundrum of interleukin-6 blockade in COVID-19.
32838323 2020. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.
32838324 2020. .
32838325 2020. Tocilizumab for severe COVID-19 pneumonia.
32838326 2020. Tocilizumab for severe COVID-19 pneumonia - Authors' reply.
32838327 2020. Tocilizumab for severe COVID-19 pneumonia.
32854738 2020. Efficacy of tocilizumab treatment in severely ill COVID-19 patients.
32854774 2020. How to follow-up a patient who received tocilizumab in severe COVID-19: a case report.
32856721 2020. Tocilizumab - A beacon of hope in the management of severe COVID-19?
32860432 2020. Tocilizumab use in COVID -19 associated pneumonia.
32860964 2020. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).
32881350 2020. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
32883328 2020. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
32886762 2020. Efficacy of Tocilizumab for treatment of severe COVID-19 Pneumonia: more evidence is needed.
32886768 2020. Therapy of Sars-Coronavirus-2 pneumonia: is there an optimal IL-6 cut-off for successful tocilizumab treatment?
32889236 2020. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
32889241 2020. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
32895645 2020. Tocilizumab for severe COVID-19 related illness - A community academic medical center experience.
32897539 2020. Potential role of subcutaneous tocilizumab injections in patients with COVID-19 associated pneumonia.
32912961 2020. Observational study on off-label use of tocilizumab in patients with severe COVID-19.

32918792 2020. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
32922212 2020. Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Facade for prognostic markers.
32929415 2020. COVACTA trial raises questions about tocilizumab's benefit in COVID-19.
32940187 2020. Tocilizumab in Sars-cov-2 Patients with the Syndrome of Cytokine Storm; a Narrative review.
32946668 2020. Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study.
32950003 2020. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.
32951190 2020. Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report.
32952047 2020. Tocilizumab for COVID-19 Pneumonia in a Patient With Non-Small-cell Lung Cancer Treated With Chemoimmunotherapy.
32952393 2020. Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature.
32953852 2020. Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients.
32954552 2020. Severe COVID-19 and interleukin-6 receptor antagonist tocilizumab: Some notes of concern.
32962623 2020. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
32963155 2020. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.
32964209 2020. Tocilizumab in COVID-19: finding the optimal route and dose.
32964210 2020. Tocilizumab in COVID-19: finding the optimal route and dose - Authors' reply.

32965395 2020. Justificativa e delineamento do estudo "Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicentrico, randomizado, controlado" (TOCIBRAS).
32979572 2020. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study.
32993751 2020. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation.
32997331 2020. Treatment of COVID-19 atypical pneumonia by early Tocilizumab administration in "non-critically-ill" patients on hemodialysis.
32999229 2020. Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Course.
33002613 2020. Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies.
33005274 2020. Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab.
33007475 2020. Tocilizumab versus the COVID-19 tempest: all's well that ends well or much ado about nothing?
33010257 2020. IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study.
33021529 2020. Tocilizumab-Associated Bowel Perforation in SARS-CoV-2 Infection.
33031060 2020. Efficacy and safety of tocilizumab in COVID-19 patients.
33035673 2020. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.
33038768 2020. Tocilizumab is recommended for the treatment of severe COVID-19.
33043164 2020. A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan.

33045577 2020. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.

33062945 2020. SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma.
33063035 2020. Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients.
33067149 2020. Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.
33072589 2020. Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia.
33075713 2020. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.
33078138 2020. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).
33079613 2020. Tocilizumab prescribing criteria for COVID-19 patients.
33079980 2020. Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia.
33080005 2020. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
33080017 2020. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
33080877 2020. Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.
33085857 2020. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
33085870 2020. Audio Interview: Tocilizumab and Covid-19.
33087150 2020. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
33089038 2020. Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.
33098139 2020. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
33115682 2020. Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia.
33123544 2020. Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis.
33127662 2020. Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study.
33127663 2020. Response to 'Neither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study' by Moiseev et al.
33132558 2020. Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers.
33154452 2020. Impact of tocilizumab administration on mortality in severe COVID-19.
33158786 2020. Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?
33158787 2020. Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.
33160536 2020. First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19.
33161002 2020. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.

33165762 2020. The effect of tocilizumab on cytokine release syndrome in COVID-19 patients.
33168277 2020. Successful treatment of a critical COVID-19 patient with tocilizumab.
33169088 2020. Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series.

33180360 2020. Treatment With Tocilizumab for Patients With COVID-19 Infections: A Case-Series Study.
33184171 2020. Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention.
33184179 2020. Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients.
33188624 2020. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
33189533 2020. Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series.
33189888 2020. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.
32661911 2020. Authors' Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19.
33190937 2020. Tocilizumab como posible causa de colitis isquemica.

33195318 2020. Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
33200828 2020. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety.
33201178 2020. The impact of tocilizumab on the mortality of patients with COVID-19.
33201228 2020. The misleading "pooled effect estimate" of crude data from observational studies at critical risk of bias: The case of Tocilizumab in COVID-19.
33203671 2020. Does tocilizumab have a magical therapeutic effect on COVID-19 patients without obvious adverse reactions?
33210302 2020. COVIDOSE: A phase 2 clinical trial of low-dose tocilizumab in the treatment of non-critical COVID-19 pneumonia.
33224347 2020. Tocilizumab in severe COVID-19.
33225307 2020. A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019.
33230415 2020. Tocilizumab for treating severe COVID-19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series.
33241872 2020. Tocilizumab administration is associated with reduction in biomarkers of coronavirus disease 2019 (COVID-19) infection.

33245278 2020. The paradoxical effect of IL-6 and implications for the use of Tocilizumab in Covid-19 patients.
33257619 2020. The shortcomings of tocilizumab in COVID-19.
33275094 2020. Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis.
33275095 2020. Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia.
33280066 2020. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.
33299621 2020. Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome.
33304913 2020. First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia.
C7308754 2020. Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases.
C7314441 2020. Can tocilizumab calm the cytokine storm of COVID-19?
C7314456 2020. Tocilizumab in patients with severe COVID-19: a retrospective cohort study.
C7318948 2020. Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation.
C7319620 ?. Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes.
C7328534 ?. Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome?.
C7329292 2020. Subcutaneous tocilizumab treatment in patients with severe COVID-19?related cytokine release syndrome: An observational cohort study.
C7348108 2020. Tocilizumab: Neutropenia: case report.
C7604050 2020. USO COMBINADO DE TOCILIZUMABE E CÉLULAS-TRONCO MESENQUIMAIS NO TRATAMENTO DA COVID-19 ? RELATO DE CASO.
C7649658 ?. Tocilizumab in the Management of COVID-19: A Preliminary Report.
C7657604 ?. What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies.
C7661810 2020. Tocilizumab/unspecified corticosteroids: Spinal epidural abscess: 2 case report.
C7677435 2020. Tocilizumab: Decrease in WBC count following an off-label use: case report.
C7677448 2020. Hydroxychloroquine/tocilizumab: Cytomegalovirus enterocolitis and hypovolaemic-shock following off-label use: case report.
C7692413 2020. Tocilizumab: Lobar pneumonia following off label use: case report.
C7726300 2020. Methylprednisolone/tocilizumab: Disseminated strongyloidiasis and off-label use: case report.
32737108 2020. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.
33080002 2020. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
32732244 2020. Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience.
32816702 2020. Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: 'Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al' by Cheng and Zhang.
33043284 2020. Sarilumab use in severe SARS-CoV-2 pneumonia.

33191263 2020. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.
C7726276 2020. Sarilumab: Thrombocytopenia during an off-label use: case report.
32620597 2020. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
32642806 2020. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
32816698 2020. Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al.
32702997 2020. IL-6 Blockade and QTc Prolongation in COVID-19.

32718345 2020. Inhibiting IL-6 in COVID-19: we are not sure.
32737105 2020. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli.
32750259 2020. COVID-19: Clean up on IL-6.
32760013 2020. Anti-IL-6Rs falter in COVID-19.
32779813 2020. Rugosic acid A, derived from Rosa rugosa Thunb., is novel inhibitory agent for NF-kappaB and IL-6/STAT3 axis in acute lung injury model.
33024459 2020. Outlook of IL-6 signaling blockade for COVID-19 pneumonia.

33195334 2020. IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections.
33216906 2020. The effect of IL-6 inhibitors on mortality among hospitalized COVID-19 patients: a multicenter study.
C7351402 ?. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia.
32679148 2020. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics.
32696001 2020. Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019.
32721528 2020. Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge.
32789663 2020. Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19.
32831940 2020. Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19.
32857671 2020. Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.

33028776 2020. Implications for White Matter Vulnerability to Anti-interleukin-6 Receptor Antibody Treatment.
33033405 2020. Preemptive interleukin-6 blockade in patients with COVID-19.
33040779 2020. Interleukin-6 role in the severity of COVID-19 and intensive care unit stay length.